Fixing gene defects with designer DNA is on the horizon after Google DeepMind launched a pioneering new AI tool.

Unboxing and giving a brief overview of the ocz Vector Solid State Drive, more information on ThinkComputers.org "Like" us on ...

Delivery of therapeutic genes is essential for gene therapy. Adeno-associated viruses (AAVs) are a prime vector for carrying gene cargoes because of ...

Objectives Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive ...

Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.

Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...

New genetic evidence reveals unexpected killers behind one of history’s deadliest military disasters.

Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...

Vitamin C is a key nutritional component in fruits, yet its concentration often changes dramatically as fruits develop.

Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check out why INO stock is a buy.